RESEARCH TRIANGLE PARK, N.C., July 21, 2015 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today members of its advisory board. The board is comprised of four leaders from industry and academia with expertise in complex molecular and macromolecular systems, biophysics, translational research, and drug discovery and development. The advisors collaborate with Cloud Pharmaceuticals' board of directors to provide insight on needs and opportunities within the pharmaceutical industry.
"The pharmaceutical industry is on the cusp of major transformation. Companies that readily apply new digital technologies to the drug design and development process will most successfully navigate this transition," says Ed Addison, Cloud Pharmaceuticals Chairman and CEO. "We see one of Cloud Pharmaceuticals' roles as being a pioneer and positive influence on the digital disruption of drug design. Our advisors validate the merits of our approach, and their expertise helps guide our ongoing research and development efforts."
Cloud Pharmaceuticals uses quantum chemistry, cloud computing, intelligent optimization and a collaborative partner network to radically improve upon traditional drug discovery, design, and development. The company's Fast Pipeline drug development method speeds time to market and capitalizes on the strengths of its Quantum Molecular Design process. This process includes functions such as target modeling, drug design, companion biomarker design, synthetic chemistry, and preclinical development outsourcing.
Members of the advisory board include:
- David N. Beratan, PhD – R.J. Reynolds Professor, Duke University
- Harold "Skip" Garner, PhD – Director, Medical Informatics and Systems Division, Virginia Bioinformatics Institute, Virginia Tech
- Robert A. Hromas, MD, FACP – Chairman, University of Florida Department of Medicine
- Martin Ogletree, PhD – Owner, Points & Assists – CV Research and Drug Development, Adjunct Professor of Pharmacology, Vanderbilt University School of Medicine
To see biographies of members of the advisory board, please visit the Advisory Board page at the Cloud Pharmaceuticals website.
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners. For information visit www.cloudpharmaceuticals.com.
SOURCE Cloud Pharmaceuticals, Inc.